Efficacy of avermectin B1 given orally against equine intestinal strongyles and Onchocera microfilaria.
Three groups of horses and ponies (N = 13, 13 and 12) were treated with ivermectin paste (0.2 mg/kg p.o.), avermectin B1 solution (0.2 mg/kg p.o.), or fenbendazole suspension (10 mg/kg via nasogastric tube). The avermectin B1 was a 1% solution in a propylene glycolglycerol formal base. Faecal strongyle egg counts were performed before, and 14, 28, 42, 56 and 70 d, after treatment. Full-thickness skin biopsies from the neck, pectoral and umbilical regions were examined for Onchocera microfilaria before treatment, and again 14 and 70 d later. Ivermectin therapy produced a significant (P less than 0.01) decrease in mean strongyle egg counts 14, 28, 42 and 56 d after treatment. Avermectin B1 therapy resulted in significant (P less than 0.01) decreases in mean strongyle egg counts 14, 28 and 42 d after treatment. All horses given ivermectin or avermectin B1 had zero strongyle egg counts 14 and 28 d after treatment. Fenbendazole failed to significantly decrease strongyle egg counts. Both ivermectin and avermectin B1 resulted in zero microfilaria counts in all horses 14 d after treatment. On day 70 the percentage decrease in microfilaria counts were 100% and 99.6% respectively. Fenbendazole failed to significantly decrease microfilaria counts. The oral administration of this formulation of avermectin B1 appeared to be highly efficacious against intestinal strongyles and Onchocera microfilaria. The duration of anti-strongyle activity was, however, significantly (P less than 0.01) shorter than that of ivermectin paste.
Mogg
T D
TD
Department of Companion Animal Medicine and Surgery, University of Queensland.
Pollitt
C C
CC
Willmore
J P
JP
Thompson
H
H
D000284:Administration, Oral; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D000977:Antiparasitic Agents; D005243:Feces / Q000469:parasitology; D005260:Female; D005273:Fenbendazole / Q000627:therapeutic use; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy / Q000662:veterinary; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008842:Microfilariae / Q000187:drug effects / Q000254:growth & development; D009824:Ointments; D009854:Onchocerca / Q000187:drug effects / Q000254:growth & development; D009855:Onchocerciasis / Q000188:drug therapy / Q000662:veterinary*; D010270:Parasite Egg Count / Q000662:veterinary; D012876:Skin Diseases, Parasitic / Q000662:veterinary; D013319:Strongyle Infections, Equine / Q000188:drug therapy*
D000871:Anthelmintics; D000977:Antiparasitic Agents; D009824:Ointments; D005273:Fenbendazole; C022120:avermectin B(1)a; D007559:Ivermectin